CDC-RFA-DP-23-0004: The National Cardiovascular Health Program
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Centers for Disease Control - NCCDPHP notices from 2023.
Centers for Disease Control - NCCDPHP offered grants of up to $2.0 million (at least $850,000) to state and local governments. It expected to make about 51 awards worth $275 million in total. Applications closed on April 25, 2023.
From the official notice on Grants.gov, last changed February 24, 2023. Checked November 7, 2026.
- Award ceiling$2.0 million
- Award floor$850,000
- Total funding$275 million
- Expected awards51
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | February 24, 2023 |
|---|---|
| Deadline | April 25, 2023 |
| Archived by Grants.gov | May 25, 2023 |
Who can apply
This opportunity was open to state and local governments.
- State governments
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Per the program’s authorizing statute or regulation: Sec 317(a) of the Public Health Service Act [42 USC 247b] only State governments, including the District of Columbia, or their bona fide agents are eligible to apply. Local health departments are eligible to compete under a separate NOFO (The Innovative Cardiovascular Health Program), and Tribes and Tribal-serving organizations are and will continue to be funded under separate NOFOs (https://www.cdc.gov/healthytribes/index.htm). FY22 House Report language asserts the significant increases to DHDSP’s budget allocations should be directed to “support, strengthen, and expand current evidence-based initiatives at the State, local, tribal, and territorial level.” Committee language further supports a continuation of DHDSP’s current efforts and “recognizes the vital importance of addressing cardiovascular disease among women and underserved communities, communities of color, those communities with limited access to information about cardiovascular health disease, and communities at risk for delaying regular monitoring of cardiovascular health as a result of the COVID–19 pandemic. The Committee supports CDC’s efforts to improve our understanding of the outcomes and health effects of COVID–19 infection, including cardiovascular disease.” [House Committee Report 117-96, p. 89. Available at: CRPT-117hrpt96.pdf (congress.gov)]More recently, FY23 House Report language directs efforts to “support, strengthen, and expand evidence-based initiatives at the State, local, tribal, and territorial level. The Committee recognizes the vital importance of addressing cardiovascular disease among women, particularly women of color, and further recognizes that the resulting costs to the health care system of unrecognized cardiovascular disease in women can be substantially reduced with appropriate public awareness and prevention”. [FY23 House Report 117-403, p. 80. Available at:CRPT-117hrpt403.pdf (congress.gov)] FY23 Explanatory Statement asserts the agreement includes an increase to strengthen and expand evidence-based heart disease and stroke prevention activities focused on high risk populations. Applicants should refer to the funding table for specific funding amounts for each state.
Is this a realistic fit?
- Past The National Cardiovascular Health Program awards averaged $2.3 million; this notice allows up to $2.0 million per award.
- Most of the program's money (96% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
This NOFO aims to implement and evaluate evidence-based strategies contributing to the prevention and management of CVD in populations at the highest risk. However, given the importance of health equity, this new NOFO also addresses social and economic factors to help health systems respond to social determinants present in their communities to offer those at risk of, or burdened with CVD, the best health outcomes possible.
Who has won The National Cardiovascular Health Program grants before
From fiscal 2021 to 2025, The National Cardiovascular Health Program (93.426) awarded $278 million across 123 grant awards, an average of $2.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| California Department of Public Health | California | 3 | $9.1 million |
| Department of State Health Services | Texas | 3 | $7.9 million |
| Health Research, Inc. | New York | 3 | $7.7 million |
| Michigan Department of Health and Human Services | Michigan | 3 | $7.0 million |
| Virginia Department of Health | Virginia | 3 | $6.4 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-DP-23-0004 still open?
No. It closed on April 25, 2023.
Who can apply for The National Cardiovascular Health Program?
Centers for Disease Control - NCCDPHP accepted applications from state and local governments. The notice adds further conditions, so read its eligibility section.
What is the deadline for The National Cardiovascular Health Program?
Closed April 25, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $2.0 million each. About $275 million in total across about 51 awards.
Who has won The National Cardiovascular Health Program grants before?
The largest recipients over five fiscal years were California Department of Public Health, Department of State Health Services, Health Research, Inc. The program made 123 awards worth $278 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)